All In Biotech

Drug Trial Radar · NCT00448747

Investigation of a New, Oral Growth Hormone Secretagogue, AEZS-130 as a Growth Hormone Stimulation Test.

A Multi-center, Study Investigating a New, Oral Growth Hormone Secretagogue (GHS)(AEZS 130, Formerly Ardana (ARD)-07) as a Growth Hormone (GH) Stimulation Test in Terms of Safety and Efficacy

Last checked: Nov 20, 2026Latest source record: Jul 23, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 101 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

101

Actual

Start

Jun 2007

Primary completion

Jul 2011

Study completion Jul 2011

Sponsor

Lead sponsor
AEterna ZentarisIndustry
Sponsor type
Industry
First posted
Mar 19, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Diagnostic
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The diagnosis of growth hormone deficiency (GHD) in adults is established by laboratory testing in patients with an appropriate clinical history of hypothalamic pituitary disease. Two tests that are considered to be gold standard tests for the diagnosis of GHD are the insulin tolerance test (ITT) and growth hormone releasing hormone (GHRH) combined with L-arginine (L-ARG). However, these tests are either bothersome (given intravenously) to the patient or are linked with side effects. Therefore, an orally available compound like AEZS-130 (formerly ARD-07), if demonstrated to be safe and providing adequate sensitivity and specificity could be a welcome alternative and/or complement to the current available tests. The intent was to recruit 40 adult GHD (AGHD) patients and 40 healthy control subjects into this trial, but the original sponsor (Ardana Biosciences Ltd.) discontinued the study for financial reasons before this was completed. At the time of withdrawal of GHRH from the market in 2008, 42 AGHD patients and 10 normal controls had completed the study at 9 US sites. This study reactivated to complete the remaining 30 matched control subjects. Additionally upon agreement with the FDA in a Special Protocol Assessment (SPA), 10 additional adult growth hormone deficient and their matched control were planned to be enrolled into this trial for a total treated population of approximatively 100 subjects.

Conditions

  • Diagnosis of Adult Growth Hormone Deficiency (AGDH)

Interventions

  • AEZS-130 (formerly ARD-07)Drug

    A single oral administration of AEZS-130 as Growth Hormone Stimulation Test

  • L-ARG+GHRHDrug

    A single administration of L-ARG+GHRH (iv bolus) followed by a 30min infusion of L-ARG as Growth Hormone Stimulation Test

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Receiver Operating Characteristic (ROC) Analysis on Peak GH (Growth Hormon) ConcentrationsTime frame: GH sampling: pre-dose and 30, 45, 60, 75, 90, 120, 150 min post-dose

Locations

13 sites in 1 country. Site status is shown where the registry gives one.

  • Celerion

    Tempe, Arizona

  • Cedars-Sinai Medical Center

    Los Angeles, California

  • Harbor-UCLA Medical Center

    Torrance, California

  • Northwestern University

    Chicago, Illinois

  • Radiant Research Inc.

    Chicago, Illinois

  • John Hopkins University

    Baltimore, Maryland

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Celerion

    Lincoln, Nebraska

  • Celerion

    Neptune City, New Jersey

  • Oregon Health & Science University

    Portland, Oregon

  • Baylor College of Medicine

    Houston, Texas

  • Cetero Research

    San Antonio, Texas

  • VA Puget Sound HCS University of Washington

    Tacoma, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.